MindRank Closes $52M Series B for AI-Driven Drug Discovery

MindRank, an AI-driven drug discovery company, has announced a $52 million Series B financing round, adding to a growing wave of capital flowing into AI applications for molecular biology and pharmaceutical research. MindRank focuses on using AI to rank and prioritize drug candidates, which addresses one of the most computationally expensive bottlenecks in the drug discovery pipeline. For developers working in computational biology, cheminformatics, or scientific AI more broadly, this raise signals that investor appetite for domain-specific AI models in life sciences remains strong. The funding will likely accelerate development of their core models and potentially expand API or platform access for research partners. Developers building scientific AI tools should watch MindRank's platform evolution as a case study in productizing domain-specific foundation models.